Active, not recruitingPhase 1NCT05249114
Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors
Studying Germ cell tumor
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Providence Health & Services
- Principal Investigator
- Hagen Kennecke, MDProvidence Health & Services
- Intervention
- Cabozantinib(drug)
- Enrollment
- 6 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2029
Study locations (1)
- Providence Portland Cancer Institute - Franz Clinic, Portland, Oregon, United States
Collaborators
Exelixis · Advanced Accelerator Applications
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05249114 on ClinicalTrials.govOther trials for Germ cell tumor
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07552233NK Cell Therapy for Malignant Solid Brain TumorsPeking University Third Hospital
- RECRUITINGNCT07314164Study of Cabozantinib in Participants With Neuroendocrine Tumors Who Have Already Received Prior TreatmentIpsen
- RECRUITINGPHASE1NCT07143812A Study to Evaluate the Safety of a Stem Cell-Based Gene and Cell Therapy in Patients With Newly Diagnosed GlioblastomaCHA University
- RECRUITINGNANCT06910306Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent GlioblastomaAlpha Tau Medical LTD.
- RECRUITINGNANCT07459101UNIty-Based MR-Linac Guided Adaptive RadioThErapy for High GraDe Glioma-4Sunnybrook Health Sciences Centre
- RECRUITINGPHASE1, PHASE2NCT07193966NG2 and DLL3 CAR-T Cells Targeting MelanomaShenzhen Geno-Immune Medical Institute
- RECRUITINGPHASE2NCT06712927Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain MetastasesStanford University
- RECRUITINGPHASE1, PHASE2NCT06712875MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric GliomasAnn & Robert H Lurie Children's Hospital of Chicago